Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: A systematic review and meta-analysis
Restricted accessReview articleFirst published online July, 2022
Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: A systematic review and meta-analysis
There are no systematic reviews yet that evaluated the effects of PE/IA in patients with optic neuritis (ON) in demyelinating diseases. A meta-analysis of available study is needed to further explore the value of plasma exchange (PE) or immunoadsorption (IA) in treating ON in demyelinating diseases.
Methods
All relevant articles published on PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), VIP Database, Wanfang, Sinomed and ophthalmology professional websites were searched. Study characteristics, demographic characteristics, clinical features and outcome measures were extracted. Response rate, adverse events (AE) rate, serious adverse event (SAE) rate, the log of the minimum angle of resolution (logMAR), visual outcome scale (VOS) and expanded disability status scales (EDSS) were evaluated using a random-effects model.
Results
35 studies were included between 1985 and 2020, containing 1191 patients. The response rates of PE and IA in acute attack of ON were 68% and 82% respectively. LogMAR (−0.60 to − 1.42) and VOS (−1.10 to −1.82) had been significantly improved from within 1 month to more than 1 month after PE treatment. Besides, we found that logMAR improved 1.78, 0.95 and 0.38, respectively ,when the time from symptom onset to the first PE/IA was less than 21 days, 21–28 days, and more than 28 days. The pooled mean difference of EDSS was −1.14.Adverse effects rate in patients with PE or IA were 0.20 and 0.06, respectively.
Conclusion
The meta-analysis provided evidence that PE/IA treatment was an effective and safe intervention, and it is recommended that early initiation of PE/IA treatment is critical.
RoesnerSAppelRGbadamosiJ, et al.Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand2012; 126: 103–108.
2.
DamatoVEvoliAIorioR. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol2016; 73: 1342–1348. 2016/09/27.
3.
BruscoliniASacchettiMLa CavaM, et al.Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmun Rev2018; 17: 195–200. 2018/01/18.
4.
PengAKinoshitaMLaiW, et al.Retinal nerve fiber layer thickness in optic neuritis with MOG antibodies: a systematic review and meta-analysis. J Neuroimmunol2018; 325: 69–73. 2018/10/07.
5.
HanMChenYNongL, et al.Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis. Medicine (Baltimore)2020; 99: e21067. 2020/07/16.
6.
Palacios-MendozaMAMartinez GinesMLMelgarejo OtaloraPJ, et al.Plasma exchange in acute attacks of demyelinating diseases of the central nervous system: clinical outcomes and predictors of response. Neurol Sci2020; 41: 2569–2574. 2020/04/06.
7.
WiendlHToykaKVRieckmannP, et al.Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol2008; 255: 1449–1463. 2008/11/14.
8.
CorteseIChaudhryVSoYT, et al.Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology2011; 77: 103–104.
9.
SkorupkaNMicleaAJalowiecKA, et al.Visual outcomes of plasma exchange treatment of steroid-refractory optic neuritis: a retrospective monocentric analysis. Transfus Med Hemother2019; 46: 417–422. 2020/01/15.
10.
KlingelRHeibgesAFassbenderCJAS. Plasma exchange and immunoadsorption for autoimmune neurologic diseases – current guidelines and future perspectives. ScienceDirect2009; 10: 129–132.
11.
LipphardtMMuhlhausenJKitzeB, et al.Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. J Clin Apher2019; 34: 381–391. 2019/01/31.
12.
MoserTHarutyunyanGKaramyanA, et al.Therapeutic plasma exchange in multiple sclerosis and autoimmune encephalitis: a comparative study of indication, efficacy and safety. Brain Sci2019; 9: 267. 2019/10/12.
13.
KosiyakulPSongwisitSUngprasertP, et al.Effect of plasma exchange in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Ann Clin Transl Neurol2020; 7: 2094–2102.
14.
KehuY. Evidence-based social science: the origin, development and prospects. Library and Information2018; 14: 1–10.
15.
SongWQuYHuangX. Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. Int Ophthalmol2019; 39: 2477–2483. 2019/03/03.
16.
BrochetBDeloireMGermainC, et al.Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis. J Clin Apher2020; 35: 281–289. Journal: Article in Press 2020/05/06.
17.
SongthammawatTSrisupa-OlanTSirithoS, et al.A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord2020; 38: 101506. Journal: Article 2019/11/16.
18.
Schulze-BonselKFeltgenNBurauH, et al.Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity testInvest Ophthalmol Vis Sci2006; 47: 1236–1240. 2006/03/01.
19.
GuoLPLiZHChenTL, et al.The prevalence of mental distress and association with social changes among postgraduate students in China: a cross-temporal meta-analysis. Public Health2020; 186: 178–184.
20.
WangXZhouQChenY, et al.Using RIGHT (reporting items for practice guidelines in healthcare) to evaluate the reporting quality of WHO guidelines. Health Res Policy System2020; 18: 1–10.
21.
YanPLaoYLuZ, et al.Health research capacity of professional and technical personnel in a first-class tertiary hospital in northwest China: multilevel repeated measurement, 2013-2017, a pilot study. Health Res Policy System2020; 18: 103.
22.
YanPYaoLLiH, et al.The methodological quality of robotic surgical meta-analyses needed to be improved: a cross-sectional study. J Clin Epidemiol2018; 109: 20–29.
23.
CHEN Yue-hongDLGENG Xing-yuanLG-j. Implement meta-analysis with non-comparative binary data in RevMan Software. Chin J Evid-based Med2014; 14: 889–896.
24.
DeschampsRGueguenAParquetN, et al.Plasma exchange response in 34 patients with severe optic neuritis. J Neurol2016; 263: 883–887.
25.
LlufriuSCastilloJBlancoY, et al.Plasma exchange for acute attacks of CNS demyelination predictors of improvement at 6 months. Neurology2009; 73: 949–953.
26.
MoriSKurimotoTUedaK, et al.Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. Jpn J Ophthalmol2018; 62: 525–530.
27.
RuprechtKKlinkerEDintelmannT, et al.Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology2004; 63: 1081–1083. 2004/09/29.
28.
TrebstCReisingAKielsteinJT, et al.Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif2009; 28: 108–115.
29.
TanSZhuangYWeiS, et al.Visual improvement of therapeutic plasma exchange for refractory optic neuritis patients in acute phase. Chin J Ocul Fundus Dis2019; 35: 255–258.
30.
TanSNgTKXuQ, et al.Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study. Ther Adv Neurol Disord2020; 13: 1–12. 2020/09/12.
31.
HoffmannFKraftAHeiglF, et al.Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Ther Adv Neurol Disord2018; 11: 1–12. 2018/06/07.
32.
KoziolekMJTampeDBahrM, et al.Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation2012; 9: 80. 2012/04/28.
33.
SchimrigkSFaissJKohlerW, et al.Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption - observational multicenter study with 147 patients. Eur Neurol2016; 75: 300–306. 2016/06/16.
34.
BonnanMValentinoRDebeugnyS, et al.Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. Journal of Neurology Neurosurgery and Psychiatry2018; 89: 346–351.
35.
HaiyanQ. Function and nursing of combination of plasma exchange and lymphocyte depletion in treatment of patients in acute stage of 0ptic neuritis. Nursing practice and research2016; 13: 67–69.
36.
AungsumartSApiwattanakulM. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: case series and review of the literature. Mult Scler Relat Disord2017; 13: 93–97. 2017/04/22.
37.
KimSHKimWHuhSY, et al.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. Journal of Clinical Neurology2013; 9: 36–42.
38.
WangKCWangSJLeeCL, et al.The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci2011; 18: 43–46.
39.
KhatriBOKramerJDukicM, et al.Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher2012; 27: 183–192.
40.
GulerAComertMDonmezA, et al.Therapeutic plasma exchange for neurologic disorders: single center experiences. Journal of Neurological Sciences-Turkish2016; 33: 244–253.
41.
PetrouPBen HurTVakninA, et al.Clinical efficacy of plasma-exchange in patients with progressive forms of multiple sclerosis and NMO-spectrum disease. Multiple Sclerosis Journal2017; 23: 94–94.
42.
ArachchillageDRMachinSJCohenH. Heparin-induced thrombocytopenia following plasma exchange in patients with demyelinating neurological disease. Int J Lab Hematol2015; 37: e75–e77. 2014/11/28.
43.
BonnanMValentinoROlindoS, et al.Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler2009; 15: 487–492.
44.
CorreiaIRibeiroJJIsidoroL, et al.Plasma exchange in severe acute relapses of multiple sclerosis - results from a Portuguese cohort. Mult Scler Relat Disord2018; 19: 148–152. 2017/12/15.
45.
EhlerJKoballSSauerM, et al.Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients. PLoS One2015; 10: e0134583. 2015/08/06.
46.
IpeTSRavalJSFernandoLP, et al.Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: a multicenter retrospective study by the ASFA neurologic diseases subcommittee. J Clin Apher2020; 35: 25–32. 2019/11/11.
47.
JiaoYCuiLZhangW, et al.Plasma exchange for neuromyelitis optica spectrum disorders in Chinese patients and factors predictive of short-term outcome. Clin Ther2018; 40: 603–612. 2018/04/03..
48.
KumawatBChoudharyRSharmaC, et al.Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders. Ann Indian Acad Neurol2019; 22: 389–394. Article.
49.
MorganSMZantekNDCarpenterAF. Therapeutic plasma exchange in neuromyelitis optica: a case series. J Clin Apher2014; 29: 171–177.
50.
PfeufferSRolfesLBormannE, et al.Comparing plasma exchange to escalated methyl prednisolone in refractory multiple sclerosis relapses. J Clin Med2019; 9: 35. 2019/12/28..
51.
VeerachitOLTSirithoSPrayoonwiwatN. Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder. Ther Apher Dial2020; 24: 453–460. 2019/11/12.
52.
YeqiongZ. Analysis of efficacy and safety of plasma exchange in patients with very late-onset neuromyelitis optica spectrum disorder. Journal of China-Japan Friendship Hospital2020; 34: 135–139.
53.
XianhongLXiaoxiaHDongjieZ, et al.Therapeutic safety and efficacy of plasma exchange in patients with neuromyelitis optica spectrum disorder: four cases. Chin J Blood Transfusion2020; 33: 22–25.
54.
OsmanCJenningsREl-GharianiK, et al.Plasma exchange in neurological disease. Pract Neurol2020; 20: 92–99. 2019/07/14.
55.
KlingelRHeibgesAFassbenderC. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption. Atheroscler Suppl2013; 14: 161–165. 2013/01/30.
56.
HeiglFHettichRArendtR, et al.Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl2013; 14: 167–173.
57.
KohlerWBuckaCKlingelR. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher2011; 26: 347–355.
